Wei Zhuo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Wei Zhuo has a total of 245 co-authors. Here are the top co-authors by number of shared publications:
- Tianhua Zhou
Department of Cell Biology, Zhejiang University School of Medicine, Hangzhou, China
21 shared publications - Liangjing Wang
Department of Gastroenterology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
12 shared publications - Wei Liu
Center for Metabolism Research, The Fourth Affiliated Hospital of Zhejiang University School of Medicine and International School of Medicine, International Institutes of Medicine, Zhejiang University 1 Department of Respiratory and Critical Care Medicine Yiwu
10 shared publications - Shujie Chen
Institution of Gastroenterology, Zhejiang University, Hangzhou, China
9 shared publications - Aifu Lin
MOE Laboratory of Biosystem Homeostasis and Protection, College of Life Sciences, Zhejiang University, Hangzhou, China
8 shared publications Chaochao Xu
8 shared publications
Latest Publications
Macropinocytosis of neutrophil extracellular trap by gastric cancer cells promotes immune escape and peritoneal metastasis
Background: Patients with gastric cancer (GC) and peritoneal metastasis (PM) have poor prognoses due to drug resistance and metastatic relapse. The mechanism underlying PM recurrence remains unclear. Objective: This study investigates the mechanisms of ascitic neutrophil extracellular traps (NETs) in promoting GC immune escape and PM recurrence. Design: Ascites from a patient with GC were analysed using flow cytometry, immunofluorescence and electron microscopy. In vitro and in vivo experiments demonstrated NETs promoted GC immune evasion. RNA sequencing and functional models identified the immune checkpoint molecule CEACAM1. Internalisation assay combined with inhibitors determined tumour cells internalised NETs via macropinocytosis. Immunofluorescence and western blot revealed that NETs upregulated CEACAM1 and programmed death-ligand 1 (PD-L1) by activating the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway. The cotranscription factor interferon regulatory factor 1(IRF1) for CEACAM1 and PD-L1 were identified by dual-luciferase reporter assays and chromatin immunoprecipitation. Conditioned medium-culture systems identified CSF2 and CSF3 as NETs-inducing factors. Combination of DNase I and PD-L1 antibody was evaluated in humanised mice, organoid-T cell cocultures and ex-vivo ascites therapy models. Results: We uncovered that macropinocytosis mediated uptake of NETs remodels an immunosuppressive microenvironment and promotes PM recurrence. Increased neutrophils and NETs in PM-relapsed ascites promote GC cell immune escape. Mechanistically, GC cells uptake NETs-DNA via macropinocytosis. Macropinocytic NETs-DNA activate the cGAS-STING-IRF1 pathway, upregulate immune-checkpoint molecules CEACAM1 and PD-L1, leading to immune escape. Moreover, clearing NETs-DNA combining with PD-L1 antibody achieves a synergistic inhibitory effect on PM. Conclusion: We highlight the importance of macropinocytosis mediated uptake of NETs in GC immune escape and PM recurrence, providing a potential combination therapeutic strategy for patients with PM.
Macropinocytosis of neutrophil extracellular trap by gastric cancer cells promotes immune escape and peritoneal metastasis
Background: Patients with gastric cancer (GC) and peritoneal metastasis (PM) have poor prognoses due to drug resistance and metastatic relapse. The mechanism underlying PM recurrence remains unclear. Objective: This study investigates the mechanisms of ascitic neutrophil extracellular traps (NETs) in promoting GC immune escape and PM recurrence. Design: Ascites from a patient with GC were analysed using flow cytometry, immunofluorescence and electron microscopy. In vitro and in vivo experiments demonstrated NETs promoted GC immune evasion. RNA sequencing and functional models identified the immune checkpoint molecule CEACAM1. Internalisation assay combined with inhibitors determined tumour cells internalised NETs via macropinocytosis. Immunofluorescence and western blot revealed that NETs upregulated CEACAM1 and programmed death-ligand 1 (PD-L1) by activating the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway. The cotranscription factor interferon regulatory factor 1(IRF1) for CEACAM1 and PD-L1 were identified by dual-luciferase reporter assays and chromatin immunoprecipitation. Conditioned medium-culture systems identified CSF2 and CSF3 as NETs-inducing factors. Combination of DNase I and PD-L1 antibody was evaluated in humanised mice, organoid-T cell cocultures and ex-vivo ascites therapy models. Results: We uncovered that macropinocytosis mediated uptake of NETs remodels an immunosuppressive microenvironment and promotes PM recurrence. Increased neutrophils and NETs in PM-relapsed ascites promote GC cell immune escape. Mechanistically, GC cells uptake NETs-DNA via macropinocytosis. Macropinocytic NETs-DNA activate the cGAS-STING-IRF1 pathway, upregulate immune-checkpoint molecules CEACAM1 and PD-L1, leading to immune escape. Moreover, clearing NETs-DNA combining with PD-L1 antibody achieves a synergistic inhibitory effect on PM. Conclusion: We highlight the importance of macropinocytosis mediated uptake of NETs in GC immune escape and PM recurrence, providing a potential combination therapeutic strategy for patients with PM.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Ephrin A1 Stimulates CCL2 Secretion to Facilitate Premetastatic Niche Formation and Promote Gastric Cancer Liver Metastasis
All cytokines tested in human cytokine array
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Ephrin A1 Stimulates CCL2 Secretion to Facilitate Premetastatic Niche Formation and Promote Gastric Cancer Liver Metastasis
All cytokines tested in human cytokine array
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Ephrin A1 Stimulates CCL2 Secretion to Facilitate Premetastatic Niche Formation and Promote Gastric Cancer Liver Metastasis
The liver is a primary target for distal metastasis of gastric cancer. The hepatic premetastatic niche (PMN) facilitates crucial communications between primary tumor and liver, thereby playing an essential role in hepatic metastasis. Identification of the molecular mechanisms driving PMN formation in gastric cancer could facilitate development of strategies to prevent and treat liver metastasis. Here, we uncovered a role for ephrin A1 (EFNA1) signaling in development of the PMN. EFNA1 overexpression in gastric cancer cells significantly increased C–C motif chemokine ligand 2 (CCL2) secretion through the Hippo–YAP pathway. Secreted CCL2 activated hepatic stellate cells (HStC) within the hepatic PMN via the WNT/β-catenin pathway. Inhibition of CCL2 significantly suppressed HStC activation and reduced liver metastasis triggered by EFNA1 signaling in gastric cancer cells. Moreover, high CCL2 expression correlated with poor survival in patients with cancer. Overall, these findings reveal that EFNA1 signaling in gastric cancer cells upregulates CCL2, which activates HStCs to engender establishment of a hepatic PMN that supports liver metastasis.Significance:Cross-talk between gastric cancer cells and hepatic stellate cells mediated by the EFNA1/CCL2 axis induces premetastatic niche development to facilitate metastatic spread, nominating CCL2 as a therapeutic target to suppress liver metastasis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Ephrin A1 Stimulates CCL2 Secretion to Facilitate Premetastatic Niche Formation and Promote Gastric Cancer Liver Metastasis
The liver is a primary target for distal metastasis of gastric cancer. The hepatic premetastatic niche (PMN) facilitates crucial communications between primary tumor and liver, thereby playing an essential role in hepatic metastasis. Identification of the molecular mechanisms driving PMN formation in gastric cancer could facilitate development of strategies to prevent and treat liver metastasis. Here, we uncovered a role for ephrin A1 (EFNA1) signaling in development of the PMN. EFNA1 overexpression in gastric cancer cells significantly increased C–C motif chemokine ligand 2 (CCL2) secretion through the Hippo–YAP pathway. Secreted CCL2 activated hepatic stellate cells (HStC) within the hepatic PMN via the WNT/β-catenin pathway. Inhibition of CCL2 significantly suppressed HStC activation and reduced liver metastasis triggered by EFNA1 signaling in gastric cancer cells. Moreover, high CCL2 expression correlated with poor survival in patients with cancer. Overall, these findings reveal that EFNA1 signaling in gastric cancer cells upregulates CCL2, which activates HStCs to engender establishment of a hepatic PMN that supports liver metastasis.Significance:Cross-talk between gastric cancer cells and hepatic stellate cells mediated by the EFNA1/CCL2 axis induces premetastatic niche development to facilitate metastatic spread, nominating CCL2 as a therapeutic target to suppress liver metastasis.
- Open Access
- 22 July 2025
- Published by Springer Nature in BMC Medicine
- Vol. 23 (1) , 1-17
Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancers
The limited response rates of immune checkpoint inhibitors in biliary tract cancers (BTC) highlight the need for effective biomarkers to optimize patient selection. Baseline tumor tissues from 125 patients with advanced BTC treated with first-line chemoimmunotherapy (chemoIO) were analyzed using targeted DNA sequencing and bulk RNA sequencing. In vitro and in vivo experiments were conducted to investigate the role of identified biomarkers in BTC. Mutations in TP53, BRCA2, cytokine genes, and high tumor mutation burden were significantly associated with treatment response. In contrast, KRAS G12D and ARID1A mutations were linked to poorer survival outcomes. High expression levels of CXCL9 and CTLA4 expression were associated with improved treatment response, prolonged progression-free survival, and overall survival. Using these biomarkers, patients were categorized into three molecular subtypes, with Type I patients demonstrating the most favorable outcomes under chemoIO. Subsequent RNA analysis revealed that elevated CXCL9 expression was associated with increased immune checkpoint expression within the tumor and heightened immune activity in the tumor microenvironment. In the mouse orthotopic cholangiocarcinoma model, CXCL9 overexpression enhanced chemoIO efficacy. Immunohistochemistry and flow cytometry showed that CXCL9 promoted T-cell infiltration and activation. In vitro experiments using multiple BTC cell lines further demonstrated that CXCL9 was essential for maintaining T cell cytotoxicity. The immune-modulatory effects of CXCL9/CTLA4 and their predictive value for treatment efficacy were further validated in a multicenter BTC cohort. This study identified several predictive biomarkers associated with the response and efficacy of chemoIO in advanced BTC, offering valuable insights into patient stratification and refining therapeutic strategies.
- 22 July 2025
- Published by Springer Nature in BMC Medicine
- Vol. 23 (1) , 1-17
Open AccessMulti-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancers
The limited response rates of immune checkpoint inhibitors in biliary tract cancers (BTC) highlight the need for effective biomarkers to optimize patient selection. Baseline tumor tissues from 125 patients with advanced BTC treated with first-line chemoimmunotherapy (chemoIO) were analyzed using targeted DNA sequencing and bulk RNA sequencing. In vitro and in vivo experiments were conducted to investigate the role of identified biomarkers in BTC. Mutations in TP53, BRCA2, cytokine genes, and high tumor mutation burden were significantly associated with treatment response. In contrast, KRAS G12D and ARID1A mutations were linked to poorer survival outcomes. High expression levels of CXCL9 and CTLA4 expression were associated with improved treatment response, prolonged progression-free survival, and overall survival. Using these biomarkers, patients were categorized into three molecular subtypes, with Type I patients demonstrating the most favorable outcomes under chemoIO. Subsequent RNA analysis revealed that elevated CXCL9 expression was associated with increased immune checkpoint expression within the tumor and heightened immune activity in the tumor microenvironment. In the mouse orthotopic cholangiocarcinoma model, CXCL9 overexpression enhanced chemoIO efficacy. Immunohistochemistry and flow cytometry showed that CXCL9 promoted T-cell infiltration and activation. In vitro experiments using multiple BTC cell lines further demonstrated that CXCL9 was essential for maintaining T cell cytotoxicity. The immune-modulatory effects of CXCL9/CTLA4 and their predictive value for treatment efficacy were further validated in a multicenter BTC cohort. This study identified several predictive biomarkers associated with the response and efficacy of chemoIO in advanced BTC, offering valuable insights into patient stratification and refining therapeutic strategies.
- Open Access
- 3 April 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Intrapleural pressure-controlled piezo-catalytic nanozyme for the inhibition of malignant pleural effusion
Malignant pleural effusion (MPE), persistently generated by thorax tumor cells at the advanced stage, remains a major challenge for cancer therapy. Herein, we develop an ultra-sensitive piezoelectric nano-system by doping ytterbium in metal-organic framework (O3P@LPYU), which can be triggered by physiological intrapleural pressure during breath. Under the gently alterative pressure, the piezoelectric nanoparticles with notable peroxidase-like activity effectively produce a burst of reactive oxygen species and induce immunogenic cell death by catalysis of carried ozone as well as peroxide in interstitial fluid. A clear and sustained biodistribution is observed in thorax effusion and tumors upon intrapleural administration of particle. Remarkably, due to the abundant substrates in oxygen-rich environment of pleural cavity, O3P@LPYU particle provides a potent reduction of MPE volume and durable inhibition of tumor growth in thorax. Our work not only develops a bio-responsive piezoelectric nano-system, but also provides a strategy for persistent suppression of MPE in clinics.
- 3 April 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-20
Open AccessIntrapleural pressure-controlled piezo-catalytic nanozyme for the inhibition of malignant pleural effusion
Malignant pleural effusion (MPE), persistently generated by thorax tumor cells at the advanced stage, remains a major challenge for cancer therapy. Herein, we develop an ultra-sensitive piezoelectric nano-system by doping ytterbium in metal-organic framework (O3P@LPYU), which can be triggered by physiological intrapleural pressure during breath. Under the gently alterative pressure, the piezoelectric nanoparticles with notable peroxidase-like activity effectively produce a burst of reactive oxygen species and induce immunogenic cell death by catalysis of carried ozone as well as peroxide in interstitial fluid. A clear and sustained biodistribution is observed in thorax effusion and tumors upon intrapleural administration of particle. Remarkably, due to the abundant substrates in oxygen-rich environment of pleural cavity, O3P@LPYU particle provides a potent reduction of MPE volume and durable inhibition of tumor growth in thorax. Our work not only develops a bio-responsive piezoelectric nano-system, but also provides a strategy for persistent suppression of MPE in clinics.
- Open Access
- 10 March 2025
- Published by Springer Nature in Cell Research
- Vol. 35 (3) , 229
Publisher Correction: Comprehensive discovery and functional characterization of the noncanonical proteome
- 10 March 2025
- Published by Springer Nature in Cell Research
- Vol. 35 (3) , 229
Open AccessPublisher Correction: Comprehensive discovery and functional characterization of the noncanonical proteome
- Open Access
- 21 January 2025
- Published by Springer Nature in The EMBO Journal
- Vol. 44 (5) , 1464-1487
Ephrin A1 functions as a ligand of EGFR to promote EMT and metastasis in gastric cancer
Distant metastasis is the major cause of gastric cancer mortality, and epidermal growth factor receptor (EGFR) activation plays critical roles in gastric cancer dissemination. However, EGFR targeting therapies in gastric cancer show only marginal effects, and the molecular mechanisms of oncogenic EGFR signaling remain poorly defined. Here, we report Ephrin A1 as a novel ligand of EGFR in gastric cancer. Ephrin A1 facilitates colonization and metastasis of gastric cancer cells in vitro and in vivo via inducing epithelial-mesenchymal transition (EMT). Ephrin A1 directly interacts with EGFR and induces EGFR dimerization, phosphorylation and activation of downstream signaling. Ephrin A1-induced EMT can be rescued by EGFR signaling inhibitors or knockout of EGFR , but not depletion of its classical receptor EphA2 . Moreover, Ephrin A1 protein level correlates with EGFR phosphorylation levels in gastric cancer patients. Collectively, our work uncovers Ephrin A1 as a functional ligand of EGFR and highlights the potential role of the Ephrin A1/EGFR/EMT regulatory axis in cancer metastasis.
- 21 January 2025
- Published by Springer Nature in The EMBO Journal
- Vol. 44 (5) , 1464-1487
Open AccessEphrin A1 functions as a ligand of EGFR to promote EMT and metastasis in gastric cancer
Distant metastasis is the major cause of gastric cancer mortality, and epidermal growth factor receptor (EGFR) activation plays critical roles in gastric cancer dissemination. However, EGFR targeting therapies in gastric cancer show only marginal effects, and the molecular mechanisms of oncogenic EGFR signaling remain poorly defined. Here, we report Ephrin A1 as a novel ligand of EGFR in gastric cancer. Ephrin A1 facilitates colonization and metastasis of gastric cancer cells in vitro and in vivo via inducing epithelial-mesenchymal transition (EMT). Ephrin A1 directly interacts with EGFR and induces EGFR dimerization, phosphorylation and activation of downstream signaling. Ephrin A1-induced EMT can be rescued by EGFR signaling inhibitors or knockout of EGFR , but not depletion of its classical receptor EphA2 . Moreover, Ephrin A1 protein level correlates with EGFR phosphorylation levels in gastric cancer patients. Collectively, our work uncovers Ephrin A1 as a functional ligand of EGFR and highlights the potential role of the Ephrin A1/EGFR/EMT regulatory axis in cancer metastasis.
- Open Access
- 15 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Ephrin A1 Stimulates CCL2 Secretion to Facilitate Premetastatic Niche Formation and Promote Gastric Cancer Liver Metastasis
All cytokines tested in human cytokine array
- 15 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Ephrin A1 Stimulates CCL2 Secretion to Facilitate Premetastatic Niche Formation and Promote Gastric Cancer Liver Metastasis
All cytokines tested in human cytokine array